Family, ACLU sue Alaska Department of Corrections for man's death due to untreated ear infection
Goose Creek Correctional Center is seen in fall. (Photo courtesy of Alaska Department of Corrections)
The family of Lewis Jordan Jr. and the American Civil Liberties Union of Alaska filed a wrongful death lawsuit this week against the Alaska Department of Corrections and several staff.
The lawsuit filed on Tuesday charges that antibiotics and medical care for an acute ear infection would have saved the life of the 53-year-old Jordan, while incarcerated in Goose Creek Correctional Center in Wasilla in March 2023.
The lawsuit alleges that corrections staff displayed 'deliberate indifference,' repeatedly ignoring Jordan's pleas for medical treatment, leaving him in extreme pain with flu-like systems for several days. His condition progressed into a fatal case of bacterial meningitis — he was hospitalized, in a coma for several weeks, until his family removed him from life support, according to the lawsuit. The family said Jordan was otherwise in good health.
A spokesperson with the Department of Corrections declined to comment, and said the state's attorney will respond in court.
The lawsuit is filed in federal court by the estate and family members of Jordan, represented by the ACLU of Alaska and Colorado-based attorney Zachary Warren.
'He was a son, a sibling and a cherished member of his family, and he unfortunately got tied up in the criminal legal system,' said Megan Edge, director of the ACLU of Alaska's Prison Project, in an interview Thursday.
'When he was returned to custody, it was for a traffic infraction, and they revoked his parole,' she said. 'And that's such a ridiculous thing to have to die for. His family is absolutely devastated.'
The family is seeking justice for his death, including compensatory and punitive damages, as well as raising awareness around systemwide concerns with DOC policies and treatment of inmates, Edge said.
Edge emphasized people in prison are at the whim of corrections staff in accessing medical treatment. Although Jordan repeatedly submitted requests to visit the medical unit and receive evaluation and treatment, he was never permitted the opportunity to see a medical provider, according to the lawsuit, which charges staff with a pattern of 'gate-keeping medical care.'
'Oftentimes what we see is this distrust from staff to inmates when incarcerated people ask for help,' Edge said. 'But having an ear infection is so common, it is something that we know how to treat. But incarcerated people don't have power over their medical care, and so they are at the mercy of this massive system.'
The lawsuit said other detainees pleaded for him to get care, and were also ignored by staff. For days, he became 'visibly weaker, sicker, and unable to even get out of bed.' When he was found unresponsive in his cell, prison staff 'instead fixated on the unsupported idea that Jordan was experiencing an overdose,' administering Narcan, according to the suit. That caused him not to receive the proper diagnostic treatments in the following hours.
DOC staff placed Jordan in shackles and a spit hood, despite being unconscious, according to the lawsuit, and transported him to the Mat-Su Regional Medical Center.
'Absolutely dehumanizing,' Edge said of the DOC practice of using the restraint device on unconscious people. 'Unfortunately, this is something that we see. He is not the only person who has passed (in-custody), and who has been transported to the hospital while they are unconscious and shackled and with a spit hood. It's so inhumane and disturbing to visualize.'
Additionally, staff's incorrect identification of an overdose severely delayed proper care at the hospital, the lawsuit charges. The severe progression of meningitis led to medical staff to place him in a medically induced coma, with no recovery. His death was 'entirely preventable,' the lawsuit charges.
During the several weeks Jordan was in a coma, he was paroled from DOC, which the lawsuit alleges 'uses this power to shield from scrutiny for deaths that are a result of its inadequate medical care.'
'He was paroled while he was unconscious. I have a hard time wrapping my head around that, because it's so hard for people in the state of Alaska to get parole, and especially after a technical violation, but even more so, like, without applying for it. So, you know, we do have questions there,' Edge said.
'What we would like to see is the department taking responsibility for the death of people, even if they're in a hospital bed, even if they're a month later because they've been on a ventilator for a month, but if they die because of what happened while they were in the care of the Department of Corrections, the Department of Corrections should absolutely be taking responsibility for their death.'
The lawsuit cites the deaths in outside hospitals that DOC similarly attributed as not being in-custody deaths, including Jimmie Singree and Angelena McCord in 2023.
Since 2022, at least 42 people have died while incarcerated in DOC custody, with at least nine identified as suicides, according to the department.
So far this year, there have been two deaths — the most recent was announced on Tuesday as Reginald Eugene Childers, Jr. who was being held pretrial at the Anchorage Correctional Complex.
'Our interest is ultimately reducing deaths in-custody,' Edge said. 'And the only way to be able to problem-solve that, is to have an accurate picture of what actually happened. Where are the gaps in care, where are the issues? And then how can we all work together to solve those? Because, like I said, those are valuable people in our community. They're someone to someone.'
Edge emphasized the need for further transparency and likely policy changes around the quality of medical care, particularly detox protocols, as well as changes to allow those with serious medical issues to be paroled.
'We do have those mechanisms, but because of how those are designed, they're very inaccessible to people,' she said. 'So there are people who are very sick, who are trying really hard to come home, but their discretionary parole is denied for arbitrary reasons, or they don't know that they can apply for geriatric or medical parole. So I think, like we do have some of the systems, but they need improvements, and they're totally achievable.'
This is the third wrongful death lawsuit filed by the ACLU since 2023. The civil rights group is seeking restitution and damages for the families of James Rider and Mark Cook Jr., who died in pretrial custody, without being convicted of a crime.
The Department of Law did not return requests for comment about the status of those lawsuits.
'Many of the people that we have seen die are pretrial defendants who are accused of low-level crimes,' Edge said.
'Alaska does not have the death sentence, but by sending people to our jails and prisons, we're sending them to a really dangerous place where death is totally possible for things that are entirely out of control,' she said. 'Overcrowding, staffing shortages, limited access to medical care, and, like, all of that becomes sort of a dangerous cocktail for people that are stuck there. And they have no ability to advocate for themselves for the conditions that they live in.'
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Business Upturn
an hour ago
- Business Upturn
Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
Darmstadt, Germany: Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the primary endpoint of BICLA dose-response relationship at Week 24 was not met Data show encouraging efficacy in a large subgroup of SLE patients with active cutaneous manifestations at baseline, including improved response rates in key disease activity measurements There is a substantial unmet treatment need for the estimated 70-80% of SLE patients who experience active cutaneous manifestations, which can profoundly impact quality of life1 Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an investigational, oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE). Although it did not meet the primary endpoint of dose-response relationship, when compared to placebo, enpatoran demonstrated improvements in measures of both systemic and cutaneous disease activity in prespecified SLE subpopulations despite standard of care (SoC), including those with active cutaneous manifestations at baseline [(CLASI-A) ≥8], and was overall well tolerated. These findings will be presented in a late-breaking oral presentation at the 2025 European Congress of Rheumatology (EULAR) in Barcelona (Abstract # LB0004). 'Analyses of Cohort B contribute to our understanding of enpatoran's potential to address the critical unmet needs for patients living with lupus, including those experiencing significant skin manifestations. These manifestations are often part of the systemic activity or flare, which can be painful and have a considerable impact on quality of life,' said principal investigator Prof. Eric Morand, from Monash University and Monash Health. 'The improvements observed in key disease measures represent a meaningful advancement in our ongoing investigation of the TLR7/8 inhibition approach for patients insufficiently managed by current therapies.' WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of oral enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus SoC over 24 weeks. The study features a unique design across two lupus cohorts, including both patients with active SLE and cutaneous lupus erythematosus (CLE). Cohort B of the study was designed to evaluate the dose-response relationship of enpatoran in reducing disease activity, based on the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response rate at Week 24 and enrolled SLE patients who had moderate or severe active disease despite SoC. Cohort B showed positive results in secondary and exploratory endpoints and within prespecified patient subpopulations. In patients with active skin disease (CLASI-A ≥8), BICLA response rates were up to 58.6% while placebo response rates were 31.7%, and up to 60.5% of patients receiving enpatoran showed a CLASI-70 response, compared with 26.8% for placebo, at Week 24. In addition, the subgroups of patients with high corticosteroid (prednisone-equivalent ≥10 mg/day) use and those with high interferon gene signature (IFN-GS) at baseline also showed higher and relevant BICLA response rates for enpatoran compared to placebo. As presented earlier this year at LUPUS 2025, Cohort A analyses from the WILLOW study showed clinically meaningful improvement in disease activity in patients with CLE and mild SLE with active lupus rash at Weeks 16 and 24. Overall, for skin-related signs and symptoms, comparable improvements were observed in Cohort B relative to Cohort A, reinforcing the potential efficacy of enpatoran in patients with cutaneous manifestations of lupus erythematosus with or without systemic disease. 'The efficacy and tolerability results from Cohort B, including among those with active skin involvement—a manifestation that affects most lupus patients—are consistent with our observations from Cohort A. The lupus rash is not only a visible symptom but is also closely linked to the underlying systemic activity of lupus,' said Jan Klatt, Head of Development Unit Neurology & Immunology for the Healthcare business of Merck. 'We are set to initiate regulatory discussions with key health authorities to determine the most effective pathway for bringing enpatoran to patients.' Enpatoran was well-tolerated and exhibited a manageable safety profile consistent with previous studies, with no new safety signals identified. Rates of treatment-emergent adverse events (TEAEs) were comparable between all enpatoran arms and placebo, ranging from 60.6% to 64.2%, and the most frequently reported TEAEs were infections and infestations. These results further support the anticipated favorable safety profile of enpatoran. About Enpatoran Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). By inhibiting TLR7/8 activation, enpatoran may help reduce pro-inflammatory cytokines and autoantibody production, potentially addressing underlying mechanisms of chronic inflammation and disease progression in lupus. With its novel proposed mechanism of action and oral administration, enpatoran has the potential to be a first-in-class treatment for patients across lupus conditions. Enpatoran is currently under clinical investigation and is not approved for any use anywhere in the world. About the Phase 2 WILLOW Clinical Study WILLOW (NCT05162586) is a randomized, double-blind, placebo-controlled Phase 2 proof of concept and dose-finding study designed to evaluate the efficacy and safety of enpatoran in patients with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). The study incorporates a basket design, including two cohorts – Cohort A including patients with CLE or SLE with active lupus rash and Cohort B including patients with active SLE. The WILLOW study aims to advance the understanding of enpatoran's therapeutic potential and to help address significant unmet needs in lupus treatment. About Lupus Erythematosus Lupus erythematosus is a chronic autoimmune disease that can affect various parts of the body, including the skin, joints, kidneys, and other organs. It occurs when the immune system mistakenly attacks healthy tissues, leading to inflammation, pain, and potential organ damage. There are multiple types of lupus, with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) being two primary forms. Symptoms can range from mild to life-threatening, often including fatigue, joint pain, rashes, and organ involvement. Lupus disproportionately impacts women and people of color, and despite available treatments, many patients experience unmet needs due to limited efficacy or side effects. Merck in Neurology and Immunology Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company's current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck's commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and generalized myasthenia gravis (gMG). About Merck Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark 'Merck' internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to to register online, change your selection or discontinue this service. 1 Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011 Oct;6(4):330-6. PMID: 22879850; PMCID: PMC3391953. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
6 hours ago
- Yahoo
Kentucky health officials warn against use of kratom
LEXINGTON, Ky. (FOX 56) — Kratom is a tropical tree found in Southeast Asia, and it has been around for hundreds of years. Its leaves are sold throughout the United States and can treat things like pain, coughing, anxiety, depression, and even opioid use disorder and withdrawal. 'It is sold in Kentucky. Usually, it will come in either an herbal powder form or in a pill form,' said Program Director for Voices of Hope Lexington, Jimmy Chadwell. Kentucky health officials warn against use of kratom Kentucky judge tells lawmakers child removal process doesn't move quick enough in abuse investigations 1 charged, shelter-in-place ended in Saunders Lane after Boone County shooting investigation In early June, the Kentucky Department for Public Health and the Kentucky Office of Drug Control Policy put out a health alert advising the public not to consume kratom products and products containing 7-hydroxymitragynine, better known as 7-OH. It is a chemical compound found in kratom. The health agencies warned that when 7-OH is concentrated or synthetically made, it can increase the risk of overdose, severe health issues, and death. Chadwell urges those using pure kratom products for their harm-reduction benefits to do so wisely. Kentuckians spend the 3rd highest share of their income on fast food Bill could make federal minimum wage $15: Kentucky among states paying less than that Kentucky sitting near bottom of rankings in environmental protection: Study 'Exercise caution. Moderate the amount you use. Never use it alone. Always have Narcan available. Okay? Because of these kratom and the 7-OH, they work on the opioid receptors. So having Narcan available is really going to save somebody's life,' he told FOX 56. Kratom is not FDA-approved and is illegal in six states. But Chadwell said that Voices of Hope, an organization for people recovering from substance abuse disorders, believes the answer is not more laws; it is more conversation. 'We believe that creating more laws surrounding drugs and drug users will not help the community. Instead, we feel that supporting increases in the availability of education and encouraging harm reduction initiatives when using any substance are the best route to go,' he said. Read more of the latest health and wellness news Health officials also said there are no guarantees that kratom products contain the ingredients the packages claim, have the correct concentrations, or are free from contaminants or other drugs. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
6 hours ago
- Yahoo
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease
TAINAN, June 12, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines multiple mechanisms, including anti-oxidative effects (Nrf2 activation), melioration of autophagy function (autolysosomal activation), anti-amyloid accumulation (β-amyloid clearance), and anti-inflammatory effects (through NF-κB inhibition) through autolysosome pathway in neurons and microglia to remove intraneuronal and extracellular amyloid accumulation, representing the first in human multi-target strategy for AD treatment. The Phase I trial showed excellent safety, tolerability, and pharmacokinetics at 100–200 mg in both healthy and elderly adults. TML-6 will now advance to a Phase II 19 site trial across the United States, Sweden, and Taiwan after FDA approval. This 12-month study will enroll 210 patients with mild cognitive impairment (MCI) or mild dementia. Primary endpoints will include neuropsychological assessments (CDR-SB, iADRS) and blood biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP), supported by brain MRI, amyloid PET scans, and ApoE genotyping. Type C FDA consultation for phase 2 trial design has completed on 13 May 2025, with trial initiation expected in April 2026, conducted by Syneos Health CRO. With its strong preclinical and clinical profile, TML-6 holds promise as both a monotherapy and in combination with anti-amyloid biologics, providing new hope for patients with Alzheimer's disease. About Merry Life Biomedical Company Merry Life Biomedical is a Taiwan-based biotechnology company focused on developing innovative therapies for neurodegenerative and age-related diseases. Leveraging advanced molecular design, pharmacological innovation, formulation optimization and global clinical development, the company is committed to addressing urgent unmet medical needs. Media ContactDr. Ih-Jen SuMerry Life Biomedical Company, +886-910-902-296Email: suihjen0704@ View original content to download multimedia: SOURCE Merry Life Biomedical Company, Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data